Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple Myeloma
NCT01969565
Terminated
The purpose of this study is to evaluate the safety and tolerability of increasing doses of carfilzomib in combination with dexamethasone
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2017
Locations: Winship Cancer Institute-Emory University, Atlanta, Georgia
Conditions: Multiple Myeloma
Register for Updates
DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation
NCT00083915
Completed
The purpose of this study is to find out if transplant with a new regimen of chemotherapy called DT PACE-Melphalan is better than transplant with Melphalan alone. DT-PACE refers to a chemotherapy regimen for multiple myeloma consisting of Dexamethasone, Thalidomide, Cisplatin or Platinol, Adriamycin or doxorubicin, Cyclophosphamide, and Etoposide. Another purpose of this study is to find out if there will be fewer side effects with the new regimen of DT PACE-Melphalan, compared to melphalan alon... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/17/2017
Locations: University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas
Conditions: Multiple Myeloma
Register for Updates
Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
NCT00524589
Terminated
RATIONALE: Calcitriol may help prostate cancer cells become more like normal cells, and to grow and spread more slowly. Dexamethasone may help calcitriol work better by making tumor cells more sensitive to the drug. Giving calcitriol together with dexamethasone may be an effective treatment for prostate cancer that did not respond to hormone therapy . PURPOSE: This phase II trial is studying how well giving calcitriol together with dexamethasone works in treating patients with prostate cancer t... Read More
Gender:
MALE
Ages:
120 years and below
Trial Updated:
10/17/2017
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Prostate Cancer
Register for Updates
UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide
NCT00574080
Terminated
Add three drugs, bortezomib, thalidomide, and dexamethasone (VTD) to the high dose chemotherapy regimen immediately before transplant (DPACE/Melphalan) to try to improve myeloma response and acquire longer survival for participants.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/17/2017
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Multiple Myeloma
Register for Updates
A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma
NCT01660750
Completed
This is a dose finding pilot study to evaluate the safety and determine the maximum tolerated dose of the combination of carfilzomib and cyclophosphamide with dexamethasone (Car-Cy-Dex) prior to autologous stem cell transplant (ASCT) in patients with newly diagnosed transplant eligible multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/16/2017
Locations: Samuel Oschin Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles, California +4 locations
Conditions: Multiple Myeloma
Register for Updates
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
NCT01789242
Completed
This is a dose finding study to evaluate the safety and determine the maximum tolerated dose of carfilzomib in patients with previously treated systemic light-chain amyloidosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/16/2017
Locations: City of Hope, Duarte, California +9 locations
Conditions: Amyloidosis, Systemic Light Chain Amyloidosis
Register for Updates
Bioequivalence of Two Ciprofloxacin 0.3%/Dexamethasone 0.1% Sterile Otic Suspensions in Otitis Media in Children With Tympanostomy Tubes
NCT01994642
Terminated
The objective of this study is to compare the relative efficacy and safety of the test formulation of ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension (Par) to the already-marketed formulation CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%) sterile otic suspension (Alcon) in the treatment of acute bacterial otitis media in children with patent tympanostomy tubes.
Gender:
ALL
Ages:
Between 6 months and 12 years
Trial Updated:
09/22/2017
Locations: Birmingham Pediatrics, Birmingham, Alabama +22 locations
Conditions: Otitis Media in Patients With Tympanostomy Tubes
Register for Updates
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
NCT00056160
Completed
Randomized subjects will receive CC-5013 plus high-dose dexamethasone or placebo appearing identical to CC-5013 plus high-dose dexamethasone in 4-week cycles. Each subject will participate in a treatment phase and a follow-up phase.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2017
Locations: Clinical Research Consultants, Inc., Hoover, Alabama +48 locations
Conditions: Multiple Myeloma
Register for Updates
Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL)
NCT01926665
Completed
The goal of this clinical research study is to find the highest tolerable dose of carfilzomib that can be given to patients with lymphoma after a stem cell transplant. The safety of this drug will also be studied. Carfilzomib is designed to block cancer cells from repairing themselves. If the cancer cells cannot repair themselves, this may cause them to die.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
09/18/2017
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates
Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion
NCT01295112
Completed
This is a study designed to determine if the addition of Ozurdex® to bevacizumab (Avastin®) eye injections reduces the need for repeat bevacizumab eye injections in patients with nonischemic central retina vein occlusion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2017
Locations: Texas Retina Associates, Dallas, Texas
Conditions: Non-Ischemic Central Retinal Vein Occlusion
Register for Updates
Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT01689987
Completed
This phase I trial studies the side effects and best dose of hydroxychloroquine when given together with cyclophosphamide, dexamethasone, and sirolimus in treating patients with multiple myeloma that has come back after a period of improvement or does not respond to treatment. Biological therapies, such as hydroxychloroquine, may stimulate the immune system in different ways and stop cancer cells from growing. Sirolimus may stop the growth of cancer cells by blocking some of the enzymes needed f... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/05/2017
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Register for Updates
Comparison Study of Transversus Abdominal Plane, Paravertebral and Epidural Blocks in Laparoscopic Colectomy
NCT02164929
Terminated
The purpose of this study is to assess the effectiveness of transversus abdominal plane (TAP) block, thoracic epidural or paravertebral block (PVB) for controlling postoperative pain when compared with opioid you self-administer in your vein using a PCA device. The primary outcome will be postoperative opioid consumption within 24 hours after surgery. A total of 120 subjects will be randomized in a 1:1:1:1 ratio to receive a TAP block, PVB, TEA or no block (PCA alone).Patients in all groups will... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/25/2017
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Laparoscopic Colorectal Resection
Register for Updates